These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 26612062)

  • 1. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS; Niskanen L; Rasmussen S; Johansen T; Fulcher G
    J Diabetes; 2016 Sep; 8(5):720-8. PubMed ID: 26612062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S; Hyllested-Winge J; Gall MA; Kaneko S; Hirao K
    J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S; Chow F; Choi DS; Taneda S; Hirao K; Park Y; Andersen TH; Gall MA; Christiansen JS;
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W; Ma J; Hong T; Liu M; Miao H; Peng Y; Wang C; Xu X; Yang T; Nielsen AM; Pan L; Liu W; Zhao W
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial.
    Fulcher GR; Christiansen JS; Bantwal G; Polaszewska-Muszynska M; Mersebach H; Andersen TH; Niskanen LK;
    Diabetes Care; 2014 Aug; 37(8):2084-90. PubMed ID: 24812432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E; Haluzík M; Canecki Varžić S; Sargin M; Macura S; Zacho J; Christiansen JS
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial.
    Niskanen L; Leiter LA; Franek E; Weng J; Damci T; Muñoz-Torres M; Donnet JP; Endahl L; Skjøth TV; Vaag A
    Eur J Endocrinol; 2012 Aug; 167(2):287-94. PubMed ID: 22660026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial.
    Onishi Y; Yamada K; Zacho J; Ekelund J; Iwamoto Y
    J Diabetes Investig; 2017 Mar; 8(2):210-217. PubMed ID: 27560769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Original paper: Efficacy and safety analysis of insulin degludec/insulin aspart compared with biphasic insulin aspart 30: A phase 3, multicentre, international, open-label, randomised, treat-to-target trial in patients with type 2 diabetes fasting during Ramadan.
    Hassanein M; Echtay AS; Malek R; Omar M; Shaikh SS; Ekelund M; Kaplan K; Kamaruddin NA
    Diabetes Res Clin Pract; 2018 Jan; 135():218-226. PubMed ID: 29183844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The co-formulation of insulin degludec and insulin aspart lowers fasting plasma glucose and rates of confirmed and nocturnal hypoglycaemia, independent of baseline glycated haemoglobin levels, disease duration or body mass index: A pooled meta-analysis of phase III studies in patients with type 2 diabetes.
    Haluzík M; Fulcher G; Pieber TR; Bardtrum L; Tutkunkardas D; Rodbard HW
    Diabetes Obes Metab; 2018 Jul; 20(7):1585-1592. PubMed ID: 29451706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P; Wojciechowski P; Siejka S; Małecki P; Hak L; Malecki MT
    Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z; Lim-Abrahan MA; Jain AB; Goh SY; Soewondo P
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
    Latif ZA; Pathan MF; Siddiqui MN; Sobhan MJ; Rahman MM; Ashrafuzzaman SM
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensifying insulin regimen after basal insulin optimization in adults with type 2 diabetes: a 24-week, randomized, open-label trial comparing insulin glargine plus insulin glulisine with biphasic insulin aspart (LanScape).
    Vora J; Cohen N; Evans M; Hockey A; Speight J; Whately-Smith C
    Diabetes Obes Metab; 2015 Dec; 17(12):1133-41. PubMed ID: 26085028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
    Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA; Yu-Gan S; Jain AB; Sobrepena LM; Racho VA
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
    Valensi P; Shaban J; Benroubi M; Kawamori R; Borzì V; Shah S; Wenying Y; Prusty V; Hansen JB; Gumprecht J;
    Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
    Soewondo P; Lindarto D; Wibisono S; Renaldi O; Dalem-Pemayun TG
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biphasic insulin Aspart 30 vs. NPH plus regular human insulin in type 2 diabetes patients; a cost-effectiveness study.
    Farshchi A; Aghili R; Oskuee M; Rashed M; Noshad S; Kebriaeezadeh A; Kia M; Esteghamati A
    BMC Endocr Disord; 2016 Jun; 16(1):35. PubMed ID: 27278922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co-formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: a randomized, controlled phase III trial.
    Rodbard HW; Cariou B; Pieber TR; Endahl LA; Zacho J; Cooper JG
    Diabetes Obes Metab; 2016 Mar; 18(3):274-80. PubMed ID: 26592732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.